Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13056595 | 0.80 | ALDH1A1 (0.42) | TSHRALDH1A1HPGDHDAC1HDAC6 | |
| SCHEMBL13056593 | 0.79 | ALDH1A1 (0.41) | TSHRALDH1A1HPGDHDAC1HDAC6 | |
| SCHEMBL13056590 | 0.79 | ALDH1A1 (0.43) | TSHRALDH1A1HPGDRECQLHDAC1 | |
| SCHEMBL13056594 | 0.76 | ALDH1A1 (0.35) | TSHRALDH1A1HPGDHDAC1HDAC6 | |
| SCHEMBL13056588 | 0.76 | ALDH1A1 (0.46) | TSHRALDH1A1HPGD | |
| SCHEMBL13056591 | 0.74 | ALDH1A1 (0.36) | TSHRALDH1A1HPGDHDAC1HDAC6 | |
| SCHEMBL19721731 | 0.72 | ALDH1A1 (0.37) | TSHRALDH1A1HPGD | |
| SCHEMBL13056587 | 0.72 | ALDH1A1 (0.37) | TSHRALDH1A1HDAC1HDAC6 | |
| SCHEMBL19721730 | 0.70 | ALDH1A1 (0.37) | TSHRALDH1A1HPGD | |
| SCHEMBL1754965 | 0.69 | ALDH1A1 (0.55) | ALDH1A1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | VENTANA MEDICAL SYSTEMS, INC. | 2010-11-25 | — | — | US | disclosed |
| US-7695929-B2 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | VENTANA MEDICAL SYSTEMS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268462-A1 | Derivatives containing oxazole, pyrazole, thiazole, nitroaryl compound, benzofurazan, triterpene, urea, thiourea, rotenoid, coumarin or cyclolignan such as 4-(2-hydroxyphenyl)-1H-benzo[b][1,4]diazepine-2(3H)-one; multiplexed diagnostic assay for multiple targets in sample; antibodies; kits | HRH4, CRBN, NCDN | TSHR 119/4885ALDH1A1 2096/4885HPGD 1355/4885 |
| US-20100297725-A1 | Haptens, hapten conjugates, compositions thereof and method for their preparation and use | CRBN, GABBR1, SHBG | TSHR 294/4885ALDH1A1 3347/4885HPGD 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.